Skip to main content
SpringerLink
Log in

Osteocardiology: The Go/No Go Theory for Clinical Trials

  • Chapter
  • First Online:
Osteocardiology

Abstract

The role of medical therapy to treat calcification in the cardiovascular system is under intense investigation. Large cohort databases have provided significant data regarding risk factors, and timing of calcification progression. However, there is no proven medical therapy to slow the progression of disease. The Go No Theory provides the foundation for potential for medical therapy, by initiating treatments early in subclinical disease for longer periods of time. This chapter will discuss the hemodynamic effects on the expression of an osteocardiac phenotype in the heart and the potential for future medical therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783–91.

    Article  PubMed  PubMed Central  Google Scholar 

  2. FHS. Framingham Heart Study Website. 2017. http://wwwframinghamheartstudyorg. Accessed 2 March 2017.

    Google Scholar 

  3. Deutscher S, Rockette HE, Krishnaswami V. Diabetes and hypercholesterolemia among patients with calcific aortic stenosis. J Chronic Dis. 1984;37:407–15.

    Article  CAS  PubMed  Google Scholar 

  4. Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L. Case-control analysis of risk factors for presence of aortic stenosis in adults (age 50 years or older). Am J Cardiol. 1985;55:744–7.

    Article  CAS  PubMed  Google Scholar 

  5. Aronow WS, Ahn C, Kronzon I, Goldman ME. Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol. 2001;88:693–5.

    Article  CAS  PubMed  Google Scholar 

  6. Mohler ER, Sheridan MJ, Nichols R, Harvey WP, Waller BF. Development and progression of aortic valve stenosis: atherosclerosis risk factors—a causal relationship? A clinical morphologic study. Clin Cardiol. 1991;14:995–9.

    Article  CAS  PubMed  Google Scholar 

  7. Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkila J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15:865–70.

    Article  CAS  PubMed  Google Scholar 

  8. Boon A, Cheriex E, Lodder J, Kessels F. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart. 1997;78:472–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Chui MC, Newby DE, Panarelli M, Bloomfield P, Boon NA. Association between calcific aortic stenosis and hypercholesterolemia: is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol. 2001;24:52–5.

    Article  CAS  PubMed  Google Scholar 

  10. Wilmshurst PT, Stevenson RN, Griffiths H, Lord JR. A case-control investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart. 1997;78:475–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chan KL, Ghani M, Woodend K, Burwash IG. Case-controlled study to assess risk factors for aortic stenosis in congenitally bicuspid aortic valve. Am J Cardiol. 2001;88:690–3.

    Article  CAS  PubMed  Google Scholar 

  12. Briand M, Lemieux I, Dumesnil JG, et al. Metabolic syndrome negatively influences disease progression and prognosis in aortic stenosis. J Am Coll Cardiol. 2006;47:2229–36.

    Article  PubMed  Google Scholar 

  13. Palta S, Pai AM, Gill KS, Pai RG. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation. 2000;101:2497–502.

    Article  CAS  PubMed  Google Scholar 

  14. Peltier M, Trojette F, Sarano ME, Grigioni F, Slama MA, Tribouilloy CM. Relation between cardiovascular risk factors and nonrheumatic severe calcific aortic stenosis among patients with a three-cuspid aortic valve. Am J Cardiol. 2003;91:97–9.

    Article  PubMed  Google Scholar 

  15. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630–4.

    Article  CAS  PubMed  Google Scholar 

  16. Pohle K, Maffert R, Ropers D, et al. Progression of aortic valve calcification: association with coronary atherosclerosis and cardiovascular risk factors. Circulation. 2001;104:1927–32.

    Article  CAS  PubMed  Google Scholar 

  17. Messika-Zeitoun D, Aubry MC, Detaint D, et al. Evaluation and clinical implications of aortic valve calcification measured by electron-beam computed tomography. Circulation. 2004;110:356–62.

    Article  PubMed  Google Scholar 

  18. Bild DE, Detrano R, Peterson D, et al. Ethnic differences in coronary calcification: the multi-ethnic study of atherosclerosis (MESA). Circulation. 2005;111:1313–20.

    Article  PubMed  Google Scholar 

  19. Lazaros G, Toutouzas K, Drakopoulou M, Boudoulas H, Stefanadis C, Rajamannan N. Aortic sclerosis and mitral annulus calcification: a window to vascular atherosclerosis? Expert Rev Cardiovasc Ther. 2013;11:863–77.

    Article  CAS  PubMed  Google Scholar 

  20. Cao J, Steffen BT, Budoff M, et al. Lipoprotein(a) levels are associated with subclinical calcific aortic valve disease in White and Black individuals: the multi-ethnic study of atherosclerosis. Arterioscler Thromb Vasc Biol. 2016;36:1003–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ten Kate GJ, Neefjes LA, Dedic A, et al. The effect of LDLR-negative genotype on CT coronary atherosclerosis in asymptomatic statin treated patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2013;227:334–41.

    Article  PubMed  Google Scholar 

  22. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008;28:777–85.

    Article  CAS  PubMed  Google Scholar 

  23. Hamirani YS, Nasir K, Blumenthal RS, et al. Relation of mitral annular calcium and coronary calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2011;107:1291–4.

    Article  CAS  PubMed  Google Scholar 

  24. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Figueiredo CP, Rajamannan NM, Lopes JB, et al. Serum phosphate and hip bone mineral density as additional factors for high vascular calcification scores in a community-dwelling: the Sao Paulo Ageing & Health Study (SPAH). Bone. 2013;52:354–9.

    Article  CAS  PubMed  Google Scholar 

  26. Rajamannan NM. Atorvastatin attenuates bone loss and aortic valve atheroma in LDLR mice. Cardiology. 2015;132:11–5.

    Article  CAS  PubMed  Google Scholar 

  27. Rajamannan NM, Edwards WD, Spelsberg TC. Hypercholesterolemic aortic-valve disease. N Engl J Med. 2003;349:717–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Rajamannan NM. Mechanisms of aortic valve calcification: the LDL-density-radius theory A: translation from cell signaling to physiology. Am J Physiol. 2010;298:H5–15.

    CAS  Google Scholar 

  29. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–80.

    Article  CAS  PubMed  Google Scholar 

  30. Hatle L, Angelsen BA, Tromsdal A. Non-invasive assessment of aortic stenosis by Doppler ultrasound. Br Heart J. 1980;43:284–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Smith MD, Kwan OL, DeMaria AN. Value and limitations of continuous-wave Doppler echocardiography in estimating severity of valvular stenosis. JAMA. 1986;255:3145–51.

    Article  CAS  PubMed  Google Scholar 

  32. Hatle L, Brubakk A, Tromsdal A, Angelsen B. Noninvasive assessment of pressure drop in mitral stenosis by Doppler ultrasound. Br Heart J. 1978;40:131–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Tonino PA, De Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–24.

    Article  CAS  PubMed  Google Scholar 

  34. Rajamannan NM. Calcific aortic valve disease in familial hypercholesterolemia: the LDL-density-gene effect. J Am Coll Cardiol. 2015;66:2696–8.

    Article  PubMed  Google Scholar 

  35. Bernoulli D. Hydrodynamica sive de viribus et motibus fluidorum commentarrii. Strasbourg: Argentoratum; 1738. p. St31.

    Google Scholar 

  36. Gerdts E, Rossebo AB, Pedersen TR, et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am J Cardiol. 2010;106:1634–9.

    Article  PubMed  Google Scholar 

  37. Cowell SJ, Newby DE, Burton J, et al. Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol. 2003;58:712–6.

    Article  CAS  PubMed  Google Scholar 

  38. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, Investigators A. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306–14.

    Article  CAS  PubMed  Google Scholar 

  39. McClelland RL, Jorgensen NW, Budoff M, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the MESA (Multi-Ethnic Study of Atherosclerosis) with validation in the HNR (Heinz Nixdorf Recall) study and the DHS (Dallas Heart Study). J Am Coll Cardiol. 2015;66:1643–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Owens DS, Katz R, Takasu J, Kronmal R, Budoff MJ, O’Brien KD. Incidence and progression of aortic valve calcium in the multi-ethnic study of atherosclerosis (MESA). Am J Cardiol. 2010;105:701–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Owens DS, Budoff MJ, Katz R, et al. Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population. JACC Cardiovasc Imaging. 2012;5:619–25.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Budoff MJ, Nasir K, Katz R, et al. Thoracic aortic calcification and coronary heart disease events: the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2011;215:196–202.

    Article  CAS  PubMed  Google Scholar 

  43. Hyder JA, Allison MA, Wong N, et al. Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study. Am J Epidemiol. 2009;169:186–94.

    Article  PubMed  Google Scholar 

  44. Rajamannan N. Wnt signaling in atherosclerosis: the Go/No Go theory for clinical trials in osteocardiology. Cardiology. 2017. (in press).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Most Sacred Heart of Jesus Cardiology and Valvular Institute, Sheboygan, Wisconsin, USA

    Nalini M. Rajamannan

Authors
  1. Nalini M. Rajamannan
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Rajamannan, N.M. (2018). Osteocardiology: The Go/No Go Theory for Clinical Trials. In: Osteocardiology. Springer, Cham. https://doi.org/10.1007/978-3-319-64994-8_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-64994-8_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-64993-1

  • Online ISBN: 978-3-319-64994-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation